This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ECPA Welcomes EFSA's Scientific Input But Sees It As Late And Fears ED Rules Will Crush Innovation In Farm Inputs

BRUSSELS, March 20, 2013 /PRNewswire/ --

Today the European Food Safety Authority's (EFSA) Scientific Committee published its opinion on identifying endocrine disrupting chemicals (EDs).  ECPA welcomed the EFSA opinion but is concerned how late the input has been requested in a process that has been rushed to meet political deadlines.  The process to create new EU rules to identify and regulate EDs, threatens to take action based on theoretical rather than proven risks, to the detriment of European industry competitiveness and the broader public good.

" ECPA  appreciates  EFSA ' s scientific  input but sees its contribution as unfortunately late  when the ED criteria are all but finalised .  It is even more perplexing why the Commission ' s own scientific committees have been absent from the d evelopment of the ED criteria " - said Friedhelm Schmider, Director General of European Crop Protection Association (ECPA).  " Endocrine disruption is a complex scientific issue and the Commission ' s own scientific committees could have made an invaluable contribution in providing clear expert advice to European regulators and politicians " .  

Ignoring established scientific principles and rushing the development of the ED criteria risks dealing a crushing blow to European industrial innovation.  The criteria as recently drafted would deny EU farmers access to essential and innovative plant protection products which they safely use today. This will deprive EU farmers of important tools at a time when productivity must rise to meet increasing demand for food.

ECPA is clear that protecting human and environmental safety should not be compromised. Satisfying this goal and retaining industry competiveness can co-exist if the ED criteria focus on actual rather than perceived risks. The EFSA opinion raises several important technical considerations which ECPA welcomed and which demand further consideration in this respect:

  • risk assessment - EDs can be treated like most other substances and risk assessment is a suitable method to evaluate the level of concern posed by EDs, i.e. consideration of actual or predicted exposure and not only hazard;
  • potency and severity - are important and relevant indicators of potential concern, and should be considered; and
  • establishing safe dose/concentrations, above which adverse effects occur, is possible.

Further input of EFSA's Scientific Committee on the many complex topics around endocrine disruption is essential.  As the scientific debate continues on these topics, robust and independent scientific advice is important to ensure European regulation addresses substantiated concerns rather than fear. A broader return to risk assessment over hazard assessment would meaningfully contribute towards this goal.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs